Quality of life has become an important aspect of the cost to utility ratio in evaluating treatment recommendations. Interest in incorporating quality of life as an end point in cancer clinical trials has intensified in recent years. As a clinical trial endpoint, quality of life at times has value equal to disease-free survival and even actual survival time. Thus, accurate quality of life information could make a major contribution to improving the management of cancer patients. Quality of life by definition is the level of performance in the major domains of life function (physical work, psychological, social, and sexual) compared with the normal level for that individual. There are different scales for measuring quality of life of cancer patients e.g. the functional living index cancer (FLIC), the Cancer Rehabilitation Evaluation System (CARES), the Functional Assessment of Cancer Therapy (FACT) and the European Organization for Research and Treatment of Cancer Questionnaire (EORTC-QLQ).